ertugliflozin / metformin (Segluromet®)

Status: Superseded

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED FEBRUARY 2019. Refer to TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only.

Statement of Advice (SOA): ertugliflozin/metformin (Segluromet) 3492 (PDF, 99Kb)

Medicine details

Medicine name

ertugliflozin / metformin (Segluromet®)

Formulation

2.5 mg/1000 mg film-coated tablet, 2.5 mg/850 mg film-coated tablet, 7.5 mg/1000 mg film-coated tablet, 7.5 mg/850 mg film-coated tablet

Reference number

3492

Indication

Adjunct to diet and exercise to improve glycaemic control in adults aged 18 years and older with type 2 diabetes mellitus:

not adequately controlled on their maximally tolerated dose of metformin alone;
on their maximally tolerated doses of metformin in addition to other medicinal products;
already being treated with the combination of ertugliflozin and metformin as separate tablets

Company

Merck Sharp & Dohme Ltd

BNF chapter

Endocrine system

Assessment type

Non-submission

Status

Superseded

Ratification by Welsh Government

23/07/2018

Date of issue

25/07/2018

NICE guidance

TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes